TFS Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

TFS Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-68,963	Closed	-$786K	–	750
2015 Q3	$786K	Buy	+68,963	New	+$920K	0.08%	401
2014 Q3	–	Sell	-32,868	Closed	-$419K	–	1036
2014 Q2	$419K	Buy	+32,868	New	+$320K	0.03%	711
2014 Q1	–	Sell	-499,516	Closed	-$3.8M	–	1346
2013 Q4	$3.8M	Sell	499,516 -714,636	-59%	-$4.53M	0.18%	160
2013 Q3	$8.84M	Sell	1,214,152 -223,167	-16%	-$1.13M	0.4%	24
2013 Q2	$2.23M	Buy	+1,437,319	New	+$2.48M	0.09%	317

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's BCRX Position: Q4 2015 in Review

TFS Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 68,963 shares — an estimated $786K sold.

TFS Capital first reported a position in BCRX in Q2 2013 and held it in 5 quarters. The position peaked at $8.84M in Q3 2013. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

TFS Capital reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
TFS Capital sold 68,963 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $786K.
TFS Capital first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 5 quarters.
TFS Capital's BioCryst Pharmaceuticals position peaked at $8.84M in Q3 2013.
118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.